A94B10 reduces the systemic inflammation caused by TLR7 hyper-response and NaR9 inhibited TLR9-dependent lethal hepatitis in mice, thus, these antibodies appear as a promising alternative treatment in SLE, RA or psoriasis [87]. This evidence concerns the gene TLR7 and systemic lupus erythematosus.